Group 1: Market Overview - The Hang Seng Index fell by 0.50%, down 121 points, closing at 24,244 points, while the Hang Seng Tech Index dropped by 1.05% [1] - The Hong Kong stock market saw a morning trading volume of HKD 125.6 billion [1] Group 2: Biotechnology Sector - The Hang Seng Biotechnology Index surged by 3.45%, with China Biopharmaceuticals (01177) rising over 15%, Zai Lab (09688) up 9%, and YaoShengBang (09885) increasing by 6.73% [1] - Ascentage Pharma (06855) rose by 5.47%, reaching a new high due to promising data from APG-2575, indicating potential for further commercialization [1] Group 3: Nuclear Energy Sector - Overnight, U.S. nuclear stocks surged, with Oklo's stock price increasing nearly 30% after a nuclear agreement with the U.S. Air Force, and Talen Energy expanding its nuclear collaboration with Amazon [1] - In Hong Kong, China General Nuclear Power (01164) rose over 4%, and China National Nuclear Corporation (02302) increased by 4.59% [1] Group 4: Banking Sector - Domestic bank stocks continued to rise, with insurance capital's stake acquisitions nearing the total for the previous 24 years, indicating a preference for quality banks [1] - Qingdao Bank (03866) increased by 5.19%, and Chongqing Bank (01963) rose by 3.44% [1] Group 5: Other Notable Stocks - Zhongxu Future (09890) rose over 7% following a buyback announcement and a partnership with Kaiying Network for AI and gaming products [1] - China Everbright Holdings (00165) increased by over 4%, as the regulatory landscape for stablecoins is being reshaped, with high demand for Circle's listing [1] - Zijin Mining (02899) rose over 5.72% as the company plans to spin off over HKD 20 billion in assets for a Hong Kong listing, potentially reshaping its gold business valuation [2] - Jiuyuan Gene (02566) surged over 16% after signing exclusive overseas commercialization agreements for multiple biopharmaceutical products with Fosun Pharma [3] - SF Express (09699) increased by 8.9% as the demand for instant retail continues to rise, with the company investing in unmanned vehicles to enhance efficiency [4] - China Rare Earth (00769) fell by 8.79% after experiencing a doubling in stock price over the previous three trading days [5]

Core Viewpoint - After a strong two-month rally, the stock price of Yaoshi Bang (9885.HK) consolidated between HKD 10-11 from June 9 to June 11, following a year-to-date increase of over 120% and a market capitalization exceeding HKD 7 billion [1][2] Group 1: Company Performance - Yaoshi Bang is expected to achieve a full turnaround to profitability in 2024, with a projected adjusted net profit of HKD 157 million, representing a year-on-year increase of 20.1% [1] - The company’s high-margin business has accelerated growth, with a transaction scale of HKD 717 million in its brand promotion business from January to April, marking a year-on-year increase of 108.1% [1] - The company’s fundamentals have shown significant improvement, validating its profit logic [1] Group 2: Strategic Initiatives - On June 3, Yaoshi Bang entered into a strategic partnership with leading collaborative robot company Yujian Technology, focusing on integrating pharmaceutical collaborative robots, AI models, and drug IoT technologies into new retail scenarios [1] - This initiative aims to explore high-value-added business opportunities targeting retail pharmacies [1] Group 3: Market Sentiment and Analyst Ratings - The company’s quality attributes have attracted significant institutional interest, with Changcheng Securities and Tianfeng Securities both issuing "Buy" ratings, while Xinda Securities is more optimistic, projecting a compound annual growth rate of 145% for net profit from 2024 to 2027 [2] - The management has demonstrated confidence through actions, including a billion-dollar buyback plan initiated in May 2025, with 5.435 million shares repurchased for over HKD 42.31 million from May 7 to June 11 [2] - The Hong Kong pharmaceutical sector remains active, with multiple policy benefits being released, indicating a potential new market rally [2]

Investment Rating - The industry investment rating is "Overweight" indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [33]. Core Insights - The manufacturing PMI for May 2025 improved to 49.5%, up by 0.5 percentage points from the previous month, with large enterprises performing better than smaller ones [9][10]. - The equipment manufacturing, high-tech manufacturing, and consumer goods manufacturing PMIs were all in the expansion zone, indicating positive growth trends in these sectors [9]. - The robot industry is seeing strategic collaborations, such as the partnership between Yujian Technology and Yaoshi Bang to develop intelligent robots for the pharmaceutical sector [13]. - Dazhu CNC has submitted an application for H-share listing in Hong Kong, focusing on PCB production equipment, with a global market share of 6.5% as of 2024 [18][19]. Summary by Sections 1. Macro Data Tracking - The manufacturing PMI for May 2025 is 49.5%, with large enterprises above the critical point and small enterprises showing slight improvement [9]. - Equipment manufacturing PMI is at 51.2%, indicating expansion, while high-energy-consuming industries are below the critical point [9][10]. 2. Robot Industry Dynamics - Yujian Technology and Yaoshi Bang signed a strategic cooperation agreement to develop intelligent robots for various pharmaceutical applications [13]. - Galaxy General has opened seven unmanned pharmacies in Beijing, utilizing humanoid robots for 24-hour service [13]. 3. Hong Kong Listing Dynamics - Dazhu CNC has applied for H-share listing, focusing on PCB production equipment, with significant revenue growth expected in 2024 [18][19]. 4. Focus on Export Chain Enterprises - Companies with proactive overseas capacity layouts may gain market share amid changing competition dynamics due to tariffs [21]. 4.1. Jiechang Drive - Jiechang Drive reported a 20.4% increase in revenue in 2024, with significant growth in medical and home products [22][24]. - The company is expanding its overseas production bases to mitigate tariff risks [24]. 4.2. Yindu Co., Ltd. - Yindu Co., Ltd. achieved a 7.8% increase in overseas sales in 2024, focusing on building a robust overseas warehouse network [28][29]. 5. Market Review - The CSI 300 index rose by 0.88%, while the machinery equipment sector outperformed with a 0.93% increase [30].

Core Viewpoint - The article discusses the strategic shift of Yaoshi Bang, a leading digital comprehensive service platform in the outpatient pharmaceutical industry, which has proposed the "Upward Move" strategy to enhance product offerings, deepen brand partnerships, and develop proprietary brands, aiming for resilient growth amidst a challenging market environment [2][7][15]. Group 1: Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [2]. - The net profit attributable to shareholders is expected to be 140.4 billion yuan, reflecting a significant decline of nearly 12%, indicating the first negative growth in five years [2]. - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm, leading to increased demands for supply chain integration capabilities [2][10]. Group 2: Company Performance - Yaoshi Bang achieved a revenue of 17.904 billion yuan in 2024, representing a year-on-year growth of 5.5%, with net profit turning positive for the first time at 30.01 million yuan, and adjusted net profit reaching 1.57 billion yuan, up 20.1% [8][11]. - The operating cash flow remained positive at 656 million yuan, showing a 45% year-on-year increase, indicating robust growth across economic cycles [8]. Group 3: Strategic Initiatives - The "Upward Move" strategy focuses on three dimensions: enriching product offerings, deepening brand collaborations, and building proprietary brands, which collectively enhance supply chain capabilities and operational service levels [2][9][15]. - Yaoshi Bang has established a comprehensive marketing system, covering 491,000 pharmacies and 330,000 grassroots medical institutions, achieving a monthly active buyer count of 433,000, showcasing strong market penetration [10][11]. - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs, with a transaction scale of 651 million yuan, reflecting a 152% year-on-year growth [11][13]. Group 4: Market Trends - The total number of pharmacies in China reached 700,881 by Q4 2024, with a year-on-year growth of 2.3%, but a quarter-on-quarter decline of 0.5%, indicating a trend of increasing store closures [4]. - The retail terminal pharmaceutical sales scale is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, while sales of health products and medical devices have seen significant declines of 24.8% and 20%, respectively [5][10].

Investment Rating - The industry investment rating is "Overweight" indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [33]. Core Insights - The manufacturing PMI for May 2025 improved to 49.5%, up by 0.5 percentage points from the previous month, with large enterprises showing better performance [9][10]. - The equipment manufacturing, high-tech manufacturing, and consumer goods manufacturing PMIs were all in the expansion zone, indicating positive growth trends in these sectors [9][11]. - The robot industry is seeing strategic collaborations, such as the partnership between Yujian Technology and Yaoshi Bang to develop intelligent robots for the pharmaceutical sector [13][18]. - Dazhu CNC has submitted an application for H-share listing in Hong Kong, focusing on PCB production equipment, with a global market share of 6.5% as of 2024 [18][19]. Summary by Sections 1. Macro Data Tracking - The manufacturing PMI for May 2025 is 49.5%, with large enterprises above the critical point and small enterprises showing a slight improvement [9]. - The production index and new orders index increased by 0.9 percentage points and 0.6 percentage points, respectively, with the production index at 50.7% [9][10]. - Equipment manufacturing PMI was 51.2%, high-tech manufacturing PMI was 50.9%, and consumer goods manufacturing PMI was 50.2%, all indicating expansion [9][11]. 2. Robot Industry Dynamics - Yujian Technology and Yaoshi Bang signed a strategic cooperation agreement to develop intelligent robots for various pharmaceutical applications [13]. - Galaxy General has opened seven unmanned pharmacies in Beijing, utilizing humanoid robots for 24-hour service [13][18]. 3. Hong Kong Listing Application - Dazhu CNC submitted an application for H-share listing on May 30, 2025, focusing on PCB production equipment with a significant market presence [18][19]. 4. Focus on Export Chain Enterprises - Companies with proactive overseas capacity layouts may gain market share amid changing competition dynamics due to tariffs [21]. - Jiechang Drive has established subsidiaries in multiple countries and is expanding its overseas production capabilities [22][24]. 5. Market Review - The CSI 300 index increased by 0.88%, while the machinery equipment sector rose by 0.93%, outperforming the CSI 300 by 0.05 percentage points [30].

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年6月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | | 庫 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 股份回購 及 執行董事增持股份 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 股份回購 茲提述本公司日期為2025年5月7日、2025年5月9日、2025年5月12日、2025年5月 13日、2025年5月14日、2025年5月15日、2025年5月16日、2025年5月19日、2025年5 月21日、2025年5月22日、2025年5月23日、2025年5月26日、2025年5月27日、2025 年6月4日 及2025年6月5日的公告（「該等公告」），內 容 有 關（其 中 包 括）其股份回 購 計 劃。本 公 司 將 根 據 市 況 及 資 金 ...

Industry Overview - In 2024, the A-share pharmaceutical industry is projected to achieve a total revenue of 2.42 trillion yuan, marking a 1.0% year-on-year decline, the first decrease in recent years [1] - The net profit attributable to shareholders is expected to be 140.4 billion yuan, representing a significant year-on-year drop of nearly 12%, the first negative growth in five years [1] - The domestic pharmaceutical market has entered a phase of stock competition, with stricter medical insurance cost control and centralized procurement becoming the norm [1][2] Company Strategy - As a leading digital comprehensive service platform in the outpatient pharmaceutical industry, the company has launched the "Upward Move" strategy in 2023, focusing on enriching products, deepening brand cooperation, and building proprietary brands [1][3] - The company achieved a revenue of 17.904 billion yuan in 2024, a year-on-year increase of 5.5%, and its net profit turned positive for the first time, reaching 30.01 million yuan [3][4] - The company has covered 491,000 pharmacies and 330,000 grassroots medical institutions, penetrating 98.9% of county-level areas and 91.2% of townships, showcasing its extensive channel advantages [4] Market Dynamics - The number of retail pharmacies in China has reached a turning point, with a total of 700,881 pharmacies as of Q4 2024, reflecting a year-on-year growth of 2.3% but a quarter-on-quarter decline of 0.5% [2] - The closure rate of pharmacies in 2024 is approximately 5.76%, up from 3.8% in 2023, indicating an accelerating trend of store closures [2] - The retail terminal drug sales scale is expected to reach 574 billion yuan in 2024, with a year-on-year growth of 3.7%, while drug sales growth is at 2.3% [2] Product Development - The company has expanded its exclusive strategic cooperation brands and proprietary brand products to over 830 SKUs in 2024, with a transaction scale of 651 million yuan, a year-on-year increase of approximately 152% [6] - The proprietary brand "Le Yaoshi" has over 250 varieties and has achieved significant market penetration, with annual sales exceeding 38 million yuan for a key product [6][7] - The self-operated business has seen a compound annual growth rate of 78% from 2021 to 2023, with the annual GMV increasing from 83 million yuan to 263 million yuan [7] Consumer Behavior - In the stock economy era, the price-performance ratio has become the primary factor influencing consumer behavior, reflecting a shift towards more rational and cautious purchasing decisions [8] - The pharmaceutical consumption market, perceived as a necessity, is also showing signs of fatigue as consumer income expectations change [8]

Group 1 - The core viewpoint is that the pharmaceutical sector is experiencing a phase of revaluation, particularly in innovative drugs, which is expected to continue in the long term [2][3][4] - The market has fully recognized the pessimistic expectations for the pharmaceutical sector, influenced by economic downturns and regulatory pressures, but it overlooks the innovation and technological aspects of the industry [3][4] - The Hang Seng Medical ETF (513060) tracks the Hang Seng Healthcare Index, which consists of 70% innovative drugs and their supply chain, indicating a focus on the recovery of innovative drug valuations and cyclical recovery [4] Group 2 - In the short term (1-3 months), the pharmaceutical index is expected to enter a phase of volatility, with a consensus on the revaluation of innovative drugs [2] - In the medium term (3-12 months), the outlook for the pharmaceutical index remains optimistic, as it is currently at a low valuation compared to historical levels [2][3] - The recovery potential for cyclical aspects of the pharmaceutical sector, such as medical devices and consumer healthcare, is significant as the economy stabilizes [3][4]

Group 1 - The core viewpoint of the articles emphasizes the alignment of government policies aimed at enhancing grassroots healthcare with the business model of Yaoshi Bang, which operates extensively in community pharmacies and clinics [1] - The policy document highlights the need to improve accessibility to grassroots medical services, an area where digital healthcare companies like Yaoshi Bang excel [1] - Yaoshi Bang has established a significant presence in the grassroots healthcare sector, covering 491,000 pharmacies and 330,000 clinics, reaching 98.9% of counties and 91.2% of townships in China, with a monthly active buyer count of 433,000 and a payment rate of 92.7% [1] Group 2 - In response to the weak testing capabilities at grassroots medical terminals, Yaoshi Bang has launched the "Spectrum Cabin" smart medical solution, deploying 14,000 instant testing devices (POCT) across over 11,000 end-users by the end of 2024 [2] - The "Spectrum Cabin" integrates POCT, clinic SaaS, and AI doctor assistance systems to provide low-cost, highly compatible medical testing services for grassroots clinics [2] - Yaoshi Bang has invested in a commercial insurance service provider, holding a 13% stake in Ruize Health, which enhances its ecosystem by forming a "prevention-diagnosis-medication" closed loop, tapping into the market potential of "common drugs + insurance" [2]